Details

Autor(en) / Beteiligte

• Mekonnen, Tefera Worku
• Birhan, Yihenew Simegniew
• Andrgie, Abegaz Tizazu
• Hanurry, Endiries Yibru
• Darge, Haile Fentahun
• Chou, Hsiao-Ying
• Lai, Juin-Yih
• Tsai, Hsieh-Chih
• Yang, Jen Ming
• Chang, Yen-Hsiang

Titel

Encapsulation of gadolinium ferrite nanoparticle in generation 4.5 poly(amidoamine) dendrimer for cancer theranostics applications using low frequency alternating magnetic field

Ist Teil von

• Colloids and surfaces, B, Biointerfaces, 2019-12, Vol.184, p.110531-110531, Article 110531

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• [Display omitted] •Gadolinium/iron oxide nanoparticles synthesized inside poly(amidoamine) dendrimer.•A nontoxic theranostics carrier with magnetic resonance T1 and T2 imaging.•Drugs can be triggered from carrier when exposure to the magnetic field. Iron oxide-based magnetic resonance imaging (MRI) contrast agents have negative contrast limitations in cancer diagnosis. Gadolinium (Gd)-based contrast agents show toxicity. To overcome these limitations, Gd-doped ferrite (Gd:Fe3O4 (GdIO) nanoparticles (NPs) were synthesized as T1-T2 dual-modal contrast agents for MRI-traced drug delivery. A theranostics GdIO encapsulated in a Generation 4.5 PAMAM dendrimer (G4.5-GdIO) was developed by alkaline coprecipitation. The drug-loading efficiency of the NPs was ∼24%. In the presence of a low-frequency alternating magnetic field (LFAMF), a maximum cumulative doxorubicin (DOX) release of ∼77.47% was achieved in a mildly acidic (pH = 5.0) simulated endosomal microenvironment. Relaxometric measurements indicated superior r1 (5.19 mM−1s−1) and r2 (26.13 mM−1s−1) for G4.5-GdIO relative to commercially available Gd-DTPA. Thus, G4.5-GdIO is promising as an alternative noninvasive MRI-traced cancer drug delivery system.